The increase in CD106 expression and associated endothelial activation contributes to the promotion of inflammation and tissue damage in several different autoimmune diseases, such as rheumatoid arthritis (RA), systemic lupus erythematous (SLE) and scleroderma [32]. Here, VCAM1 is linked to systemic lupus erythematosus.